ono-4007

ONO-4007 is a **synthetic analogue of the lipid A moiety** of bacterial lipopolysaccharide, developed as an antitumor agent. Its mechanism involves **inducing intratumoral tumor necrosis factor alpha (TNF-α)**, potentiating tumor-infiltrating macrophages, inhibiting angiogenesis, and stimulating Th1-type immune responses via cytokine cascades. ONO-4007 upregulates cytokines such as IL-1α, IL-6, and IL-12, which activates cytotoxic natural killer (NK) cells, inducing IFN-γ and nitric oxide synthase (NOS) activity. It is distinguished from other lipid A analogs and lipopolysaccharides by **lower systemic toxicity**, a stable pharmacokinetic profile, and selective cytokine induction primarily in primed monocytes/macrophages. ONO-4007 was investigated in clinical trials for cancer, where it showed some disease stabilization but no objective tumor responses, and development was discontinued after Phase I[1][2][3][4][5].

Other names

ono 4007ono4007ono-4007DT-5461DT5461DT 5461